In8bio Inc (INAB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $8.82M
Last updated: Nov 17, 2026 at 4:13 PM ET
In8bio Inc (INAB) Statistics
In8bio (INAB) has a market cap of $8.82M. Its share count is up 329.14% from a year earlier. It holds $13.97M more cash than debt, 158.43% of its market cap.
Total Valuation
| Market Cap | $8.82M |
|---|---|
| Latest price (Nov 17, 2026) | $0.82 |
Key Dates
The next earnings report is expected on Mar 10, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 10, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 48.43% over 52 weeks and trades 24.77% below its 50-day average.
| Beta (1Y) | 1.40 |
|---|---|
| 52-Week Change | -48.43% |
| 1-Month Change | -24.77% |
| 3-Month Change | -31.67% |
| 6-Month Change | -43.45% |
| 5-Year Change | -99.60% |
| Total Return (1Y) | -48.43% |
| Total Return (3Y CAGR) | -68.91% |
| Total Return (5Y CAGR) | -67.23% |
| Max Drawdown (1Y) | -68.49% |
| Max Drawdown (3Y) | -98.84% |
| Sharpe Ratio (1Y) | -0.82 |
| Correlation with SPY (1Y) | 0.23 |
| 50-Day Average | $1.09 |
| 200-Day Average | $1.37 |
| 52-Week Range | $0.72 to $2.73 |
| RSI (14 Days) | 35.2 |
| Average Volume (20 Days) | 293.78K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 5.78x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 5.78x |
|---|---|
| Quick Ratio | 5.78x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -136.91% and return on assets is -103.80% over the last 12 months.
| Return on Equity (ROE) | -136.91% |
|---|---|
| Return on Assets (ROA) | -103.80% |
| Return on Capital Employed (ROCE) | -120.78% |
| ROA (5Y Average) | -83.12% |
| ROIC (5Y Average) | -55.73% |
Scores
INAB has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 3 of 9 |
|---|---|
| Piotroski Strength | Average |
Income Statement
Revenue of $0 over the last 12 months is down 100.00% from the 12 months before.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$1.17M |
| Operating Income | -$19.41M |
| Pretax Income | -$19.41M |
| Net Income | -$19.41M |
| EBITDA | -$17.49M |
| EBIT | -$19.41M |
| Reported EPS (TTM) | -$1.20 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 75.78% of the $18.70M in total assets.
| Cash and Equivalents | $13.97M |
|---|---|
| Total Debt | $0 |
| Net Cash | $13.97M |
| Net Cash Per Share | $0.72 |
| Working Capital | $12.57M |
| Shareholder Equity | $14.17M |
| Book Value Per Share | $0.73 |
| Total Assets | $18.70M |
| Total Liabilities | $4.52M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $243.00K of capital spending, operating cash flow left -$15.00M of free cash flow.
| Operating Cash Flow | -$14.76M |
|---|---|
| Capital Expenditures | $243.00K |
| Free Cash Flow | -$15.00M |
| FCF Per Share | -$1.52 |
| Depreciation and Amortization | $1.91M |
Trailing 12 months through Sep 30, 2026.
Dividends and Yields
INAB does not pay a dividend.
| Buyback Yield | -115.84% |
|---|---|
| Shareholder Yield | -115.84% |
Stock Splits
The last split was a 1-for-30 reverse split on Jun 6, 2025.
| Last Split Date | Jun 6, 2025 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:30 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About INAB
What is INAB's market cap?
In8bio has a market cap of $8.82M.
How many shares of INAB are outstanding?
In8bio has 19.47M shares outstanding. The count is up 329.14% from a year earlier.
Does INAB pay a dividend?
No. In8bio does not pay a dividend.
How much debt does INAB have?
In8bio has $0 of total debt and $13.97M of cash and equivalents, a net cash position of $13.97M.
INAB pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors